ABK Biomedical raises $35 million USD to bring liver cancer treatment to market
Series D funding will support commercialization of Halifax company's Eye90 microspheres. Halifax-based ABK Biomedical has raised $35 million USD ($49.1...
Biomedical
Series D funding will support commercialization of Halifax company's Eye90 microspheres. Halifax-based ABK Biomedical has raised $35 million USD ($49.1...
